|
Factors
|
Total (n = 118)
|
High (n = 37)
|
Low (n = 81)
|
P (High vs Low)
|
|---|
|
Median age at diagnosis (y)
|
65 (47–81)
|
65 (47–76)
|
66 (49–81)
|
0.087
|
|
Median PSA at diagnosis (ng/mL)
|
61.0 (5.0–21,114)
|
61.2 (3.2–21,114)
|
61.0 (5.0–9430)
|
0.840
|
|
GS at diagnosis≥9
|
70 (61%)
|
25 (68%)
|
45 (55%)
|
0.290
|
|
Metastatic status at diagnosis
|
No: 34 (29%)
|
No: 11 (30%)
|
No: 23 (28%)
|
0.528
|
|
LN:15 (13%)
|
LN:5 (14%)
|
LN:10 (12%)
|
|
Bone< 6:37 (31%)
|
Bone< 6:8 (22%)
|
Bone< 6:29 (36%)
|
|
Bone> 5:24 (20%)
|
Bone> 5:10 (27%)
|
Bone> 5:14 (17%)
|
|
Visceral:8 (7%)
|
Visceral:3 (8%)
|
Visceral:5 (6%)
|
|
Median age at CBZ start (y)
|
70 (48–88)
|
70 (48–79)
|
72 (50–88)
|
0.182
|
|
Median PSA at CBZ start (ng/ml)
|
75.2 (0.07–9586)
|
52.3 (3.44–1610)
|
78.0 (0.07–9586)
|
0.550
|
|
PS at CBZ start≥1
|
62 (53%)
|
13 (35%)
|
49 (60%)
|
0.017*
|
|
Median RDI of CBZ
|
60% (30–100%)
|
75% (60–100%)
|
60% (30–80%)
|
< 0.001*
|
- PS performance status, RDI relative dose intensity *P < 0.05
